GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Khiron Life Sciences Corp (OTCPK:KHRNF) » Definitions » Cyclically Adjusted PB Ratio

Khiron Life Sciences (Khiron Life Sciences) Cyclically Adjusted PB Ratio : 0.04 (As of Jun. 09, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Khiron Life Sciences Cyclically Adjusted PB Ratio?

As of today (2024-06-09), Khiron Life Sciences's current share price is $0.009. Khiron Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2022 was $0.24. Khiron Life Sciences's Cyclically Adjusted PB Ratio for today is 0.04.

The historical rank and industry rank for Khiron Life Sciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

KHRNF's Cyclically Adjusted PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.875
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Khiron Life Sciences's adjusted book value per share data for the three months ended in Sep. 2022 was $0.094. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.24 for the trailing ten years ended in Sep. 2022.

Shiller PE for Stocks: The True Measure of Stock Valuation


Khiron Life Sciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Khiron Life Sciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Khiron Life Sciences Cyclically Adjusted PB Ratio Chart

Khiron Life Sciences Annual Data
Trend May12 May13 May14 May15 May16 May17 Dec18 Dec19 Dec20 Dec21
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Khiron Life Sciences Quarterly Data
Nov17 Feb18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.74 0.36 0.30

Competitive Comparison of Khiron Life Sciences's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Khiron Life Sciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Khiron Life Sciences's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Khiron Life Sciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Khiron Life Sciences's Cyclically Adjusted PB Ratio falls into.



Khiron Life Sciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Khiron Life Sciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.009/0.24
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Khiron Life Sciences's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2022 is calculated as:

For example, Khiron Life Sciences's adjusted Book Value per Share data for the three months ended in Sep. 2022 was:

Adj_Book=Book Value per Share/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=0.094/120.6479*120.6479
=0.094

Current CPI (Sep. 2022) = 120.6479.

Khiron Life Sciences Quarterly Data

Book Value per Share CPI Adj_Book
201211 1.121 96.313 1.404
201302 0.999 96.945 1.243
201305 0.901 97.182 1.119
201308 0.763 97.261 0.946
201311 0.673 97.182 0.836
201402 0.504 98.051 0.620
201405 0.386 99.394 0.469
201408 0.205 99.315 0.249
201411 0.098 99.078 0.119
201502 0.032 99.078 0.039
201505 0.179 100.263 0.215
201508 0.058 100.579 0.070
201511 0.021 100.421 0.025
201602 -0.005 100.421 -0.006
201605 -0.280 101.765 -0.332
201608 -0.338 101.686 -0.401
201611 -0.380 101.607 -0.451
201702 -0.427 102.476 -0.503
201705 -0.417 103.108 -0.488
201708 -0.130 103.108 -0.152
201711 0.150 103.740 0.174
201802 0.081 104.688 0.093
201806 0.109 105.557 0.125
201809 0.204 105.636 0.233
201812 0.253 105.399 0.290
201903 0.391 106.979 0.441
201906 0.589 107.690 0.660
201909 0.546 107.611 0.612
201912 0.456 107.769 0.510
202003 0.379 107.927 0.424
202006 0.362 108.401 0.403
202009 0.328 108.164 0.366
202012 0.328 108.559 0.365
202103 0.291 110.298 0.318
202106 0.275 111.720 0.297
202109 0.242 112.905 0.259
202112 0.145 113.774 0.154
202203 0.130 117.646 0.133
202206 0.111 120.806 0.111
202209 0.094 120.648 0.094

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Khiron Life Sciences  (OTCPK:KHRNF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Khiron Life Sciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Khiron Life Sciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Khiron Life Sciences (Khiron Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5
Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.